Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Burkitt Lymphoma 1

Interventions

Vincristine 7Cyclophosphamide 7Methotrexate 6Dexamethasone 6Cytarabine 6merphos 5Mercaptopurine 5Doxorubicin 5pegaspargase 4dexamethasone acetate 4dexamethasone 21-phosphate 4blinatumomab 4azathiopurine 4auricularum 4Prednisone 4Leucovorin 4Inotuzumab Ozogamicin 4Calcium Dobesilate 4prednylidene 3deltacortene 3Thioguanine 3Specimen Handling 3N,N-dicyclohexyl-isoborneol-10-sulfonamide 3Methylprednisolone 3Asparaginase 3calaspargase pegol 2asparaginase erwinia chrysanthemi recombinant 2Spinal Puncture 2Rituximab 2Radiotherapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma × ofatumumab × 90 days × Clear all
NCT02877303 2026-05-20

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
80 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡